Gadoteridol

Gadoteridol (INN) is a gadolinium-based MRI contrast agent, used particularly in the imaging of the central nervous system. It is sold under the brand name ProHance.^[3] Gadoteridol was first approved for use in the United States in 1992.^[4]

Gadoteridol

Clinical data
Other names	(10-(2-(hydroxy-κO)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3−)-κN1,κN4,κN7,κN10,κO1,κO4,κO7)-gadolinium
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of administration	IV
ATC code	V08CA04 (WHO)
Legal status
Legal status	CA: ℞-only[1] US: WARNING[2]Rx-only
Identifiers
IUPAC name gadolinium(+3) cation; 2-[4-(2-hydroxypropyl)-7,10-bis(2-oxido-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate
CAS Number	120066-54-8 Y
PubChem CID	60714
DrugBank	DB00597 Y
ChemSpider	54719 Y
UNII	0199MV609F
KEGG	D01137 Y
ChEBI	CHEBI:31643 Y
ChEMBL	ChEMBL1200593 N
CompTox Dashboard (EPA)	DTXSID2048662
Chemical and physical data
Formula	C17H29GdN4O7
Molar mass	558.69 g·mol−1
3D model (JSmol)	Interactive image
SMILES [Gd+3].[O-]C(=O)CN1CCN(CCN(CCN(CC(O)C)CC1)CC([O-])=O)CC([O-])=O
InChI InChI=1S/C17H32N4O7.Gd/c1-14(22)10-18-2-4-19(11-15(23)24)6-8-21(13-17(27)28)9-7-20(5-3-18)12-16(25)26;/h14,22H,2-13H2,1H3,(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3 Y Key:DPNNNPAKRZOSMO-UHFFFAOYSA-K Y
NY (what is this?)  (verify)

References

1. "Prohance Product information". Health Canada. 30 July 1998. Retrieved 19 April 2024.
2. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
3. Bracco Diagnostic Inc. (26 October 2022). "Gadoteridol (ProHance) prescribing information". DailyMed. U.S. National Library of Medicine. Retrieved 17 May 2023.
4. Morgan DE, Spann JS, Lockhart ME, Winningham B, Bolus DN (April 2011). "Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients". Radiology. 259 (1): 109–16. doi:10.1148/radiol.10100906. PMID 21248237. Specifically, the rate of nausea (0.530%) was less than half the rate (1.4%) in clinical trials of 1251 patients, leading to FDA approval in 1992.